Clofazimine

DB00845ApprovedInvestigationalWithdrawnSmall moleculeAntimycobacterials

Clofazimine is a riminophenazine antimycobacterial used to treat leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids.

Chemical structure of Clofazimine
Mechanism
Curator reviewed · 4 references
Primary indication
Clofazimine is indicated for the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.Curator reviewed · 1 structured indication
Formula / weight
C27H22Cl2N4 · 473.396 g/mol (avg)
First approval
United States, 1986
Also known as
Riminophenazine
Code names
B 663 · G-30320 · NSC-141046
Brand names
  • Lamprene

Resolves to

Structure
InChIKeyWDQPAMHFFCXSNU-BGABXYSRSA-NSMILESCC(C)N=C1C=C2N(C3=CC=C(Cl)C=C3)C3=C(C=CC=C3)N=C2C=C1NC1=CC=C(Cl)C=C1

What you can answer from here — as of August 31, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
3TransportersSubstrate / inhibitor direction, not just membership
Listed above
776Drug interactionsStructured to mechanism, not free text
Sign in
48Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
8Marketed productsAcross 4 countries and 5 labellers
Sign in
2ATC codesIncluding every combination product, plus 26 drug categories
Sign in
22+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Clofazimine, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account